Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Prevnar Capacity Expansion Planned For 2003; Shortage Until Then

Executive Summary

Wyeth plans to add a second Prevnar production line during 2003 to help alleviate supply problems with the pneumococcal conjugate vaccine

You may also be interested in...



Premarin/Prempro Rxs Stabilize; Wyeth Predicts $300 Mil. Drop In 2nd Half

Wyeth is seeing some stabilization in the Premarin franchise despite a 40% drop in prescriptions for Prempro and a 15% decline in Premarin scripts since release of the Women's Health Initiative study results

Premarin/Prempro Rxs Stabilize; Wyeth Predicts $300 Mil. Drop In 2nd Half

Wyeth is seeing some stabilization in the Premarin franchise despite a 40% drop in prescriptions for Prempro and a 15% decline in Premarin scripts since release of the Women's Health Initiative study results

Flu Vaccine Schedule Expansion Could Cost Public Sector $60 Mil. Annually

Expanding influenza vaccination recommendations to include infants between six and 23 months and children who are household contacts of high-risk groups could increase costs to the public sector by $59.6 mil. annually

Related Content

UsernamePublicRestriction

Register

PS039761

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel